MA45225A - Complexes radiopharmaceutiques - Google Patents

Complexes radiopharmaceutiques

Info

Publication number
MA45225A
MA45225A MA045225A MA45225A MA45225A MA 45225 A MA45225 A MA 45225A MA 045225 A MA045225 A MA 045225A MA 45225 A MA45225 A MA 45225A MA 45225 A MA45225 A MA 45225A
Authority
MA
Morocco
Prior art keywords
radiopharmaceutical complexes
radiopharmaceutical
complexes
Prior art date
Application number
MA045225A
Other languages
English (en)
Inventor
Alan Cuthbertson
Stefanie Hammer
Jenny Karlsson
Mark Trautwein
Ernst Weber
Original Assignee
Bayer As
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As, Bayer Pharma AG filed Critical Bayer As
Publication of MA45225A publication Critical patent/MA45225A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045225A 2016-06-10 2017-06-06 Complexes radiopharmaceutiques MA45225A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16173874 2016-06-10

Publications (1)

Publication Number Publication Date
MA45225A true MA45225A (fr) 2019-04-17

Family

ID=56132786

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045225A MA45225A (fr) 2016-06-10 2017-06-06 Complexes radiopharmaceutiques

Country Status (26)

Country Link
US (1) US20190298865A1 (fr)
EP (1) EP3468619A1 (fr)
JP (1) JP2019517547A (fr)
KR (1) KR20190016544A (fr)
CN (1) CN109689115A (fr)
AR (1) AR110466A1 (fr)
AU (1) AU2017277463A1 (fr)
BR (1) BR112018075554A2 (fr)
CA (1) CA3026900A1 (fr)
CL (1) CL2018003550A1 (fr)
CO (1) CO2018013359A2 (fr)
CR (1) CR20180581A (fr)
CU (1) CU20180149A7 (fr)
DO (1) DOP2018000277A (fr)
EA (1) EA201892814A1 (fr)
EC (1) ECSP18091468A (fr)
IL (1) IL263538A (fr)
MA (1) MA45225A (fr)
MX (1) MX2018015340A (fr)
NI (1) NI201800136A (fr)
PE (1) PE20190327A1 (fr)
PH (1) PH12018502605A1 (fr)
SG (1) SG11201810967VA (fr)
TW (1) TW201805025A (fr)
UY (1) UY37286A (fr)
WO (1) WO2017211809A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2020061435A1 (fr) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
KR102819704B1 (ko) 2018-11-21 2025-06-11 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서의 작용화된 헤테로사이클
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR20220032078A (ko) 2019-07-08 2022-03-15 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도
EP3763726A1 (fr) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
EP3997103B9 (fr) 2019-07-08 2025-02-26 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
TW202116733A (zh) 2019-07-25 2021-05-01 挪威商拜耳公司 用於癌症診斷及治療之靶向放射性藥品
WO2021055425A2 (fr) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
WO2021188414A1 (fr) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Composés hétérocycliques fonctionnalisés utiles en tant qu'agents antiviraux
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
JP2024503637A (ja) 2021-01-07 2024-01-26 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
EP4050018A1 (fr) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
US20250186630A1 (en) 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4880615A (en) 1988-11-25 1989-11-14 Merck & Co., Inc. Stabilized radiopharmaceutical compositions
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP5352460B2 (ja) 2006-08-15 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ルミネッセント大環状ランタニド錯体
JP2013506664A (ja) * 2009-10-02 2013-02-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
AU2010336403B2 (en) * 2009-12-24 2016-04-21 Lumiphore, Inc. Radiopharmaceutical complexes
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
NL2009131C2 (en) * 2012-07-05 2014-01-07 Stichting Vu Vumc Compound and use of compound to prepare a radiollabelled compound.
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques

Also Published As

Publication number Publication date
EP3468619A1 (fr) 2019-04-17
EA201892814A1 (ru) 2019-06-28
CA3026900A1 (fr) 2017-12-14
PH12018502605A1 (en) 2019-10-21
CO2018013359A2 (es) 2018-12-14
WO2017211809A1 (fr) 2017-12-14
AR110466A1 (es) 2019-04-03
UY37286A (es) 2018-01-31
MX2018015340A (es) 2019-03-28
CR20180581A (es) 2019-02-11
SG11201810967VA (en) 2019-01-30
CL2018003550A1 (es) 2019-02-01
NI201800136A (es) 2019-04-29
AU2017277463A1 (en) 2019-01-03
CU20180149A7 (es) 2019-07-04
BR112018075554A2 (pt) 2019-10-01
ECSP18091468A (es) 2018-12-31
DOP2018000277A (es) 2018-12-31
KR20190016544A (ko) 2019-02-18
US20190298865A1 (en) 2019-10-03
IL263538A (en) 2019-01-31
CN109689115A (zh) 2019-04-26
TW201805025A (zh) 2018-02-16
JP2019517547A (ja) 2019-06-24
PE20190327A1 (es) 2019-03-05

Similar Documents

Publication Publication Date Title
MA45225A (fr) Complexes radiopharmaceutiques
IL259706B (en) Hybrid inspectors
DK3405050T3 (da) Børnesikret snusbeholder
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
KR20180084876A (ko) 내플라즈마성 부재
DK3445708T3 (da) Stigbøjle
MA41176A (fr) Complexes radio-pharmaceutiques
SMT202200173T1 (it) Composti
DK3452590T3 (da) Plademagnet
DK3509963T3 (da) Pallecontainer
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
EP3379969A4 (fr) Valise
DK3551355T3 (da) Immobiliseret indsats
EP3399976C0 (fr) Amphophiles de benzothiazole
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DE112017006386A5 (de) Schraubarbeitszylinder
DK3323708T3 (da) Bovfender
DK3452587T3 (da) Penicillin-g-acylaser
DK3430609T3 (da) Smartflag
EP3400237A4 (fr) Analogues peptidiques
DK3471535T3 (da) Dyrelift
DK3436447T3 (da) Isoquinolinyl-triazolon-komplekser
DK3295800T3 (da) Sandwichkiksindretning